Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system

Antiviral Research

Volumn 91, Issue 2, 2011, Pages 94-98

  Jegede, Oyebisi ^a,b,d   Khodyakova, Ana ^a   Chernov, Mikhail ^a,f   Weber, Jan ^a,e   Menéndez Arias, Luis ^c   Gudkov, Andrei ^a,f   Quiñones Mateu, Miguel E ^a,g  

^a LERNER RESEARCH INSTITUTE   (United States)

^b KENT STATE UNIVERSITY   (United States)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d Northside Medical Center   (United States)

^e Quidel Corporation   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Drug resistance; Drug screening; Fitness; HIV; Reverse transcriptase inhibitors

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; CBL 17; CBL 21; CBL 4; GREEN FLUORESCENT PROTEIN; INDOLOPYRIDINONE; LENTIVIRUS VECTOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR WEIGHT; MOLECULE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS RECOMBINANT; VIRUS RESISTANCE;

ANTI-HIV AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; GREEN FLUORESCENT PROTEINS; HIGH-THROUGHPUT SCREENING ASSAYS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR WEIGHT; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79958278570     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.05.004     Document Type: Article

References (21)

1. Blanco J., Clotet-Codina I., Bosch B., Armand-Ugon M., Clotet B., Este J.A. Multiparametric assay to screen and dissect the mode of action of anti-human immunodeficiency virus envelope drugs. Antimicrob. Agents Chemother 2005, 49:3926-3929.
2. de Bethune M.P. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res. 2010, 85:75-90.
3. De Meyer S., Azijn H., Surleraux D., Jochmans D., Tahri A., Pauwels R., Wigerinck P., de Bethune M.P. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother 2005, 49:2314-2321.
4. Ehteshami M., Scarth B.J., Tchesnokov E.P., Dash C., Le Grice S.F., Hallenberger S., Jochmans D., Gotte M. Mutations M184V and Y115F in HIV-1 reverse transcriptase discriminate against " nucleotide-competing reverse transcriptase inhibitors" J. Biol. Chem. 2008, 283:29904-29911.
5. Gurova K.V., Hill J.E., Guo C., Prokvolit A., Burdelya L.G., Samoylova E., Khodyakova A.V., Ganapathi R., Ganapathi M., Tararova N.D., Bosykh D., Lvovskiy D., Webb T.R., Stark G.R., Gudkov A.V. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc. Natl. Acad. Sci. USA 2005, 102:17448-17453.
6. Jochmans D., Deval J., Kesteleyn B., Van Marck H., Bettens E., De B., Dehertogh P., Ivens T., Van Ginderen M., Van Schoubroeck B., Ehteshami M., Wigerinck P., Gotte M., Hertogs K. Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action. J.Virol. 2006, 80:12283-12292.
7. Jochmans D., Van Ginderen M., De Baere I., Dehertogh P., Hallenberger S., Hertogs K. The in vitro resistance profile of NcRTI-1 is complementary with the resistance profile of tenofovir and zidovudine. Antivir. Ther. 2006, 11:S21.
8. Johnson V.A., Brun-Vezinet F., Clotet B., Gunthard H.F., Kuritzkes D.R., Pillay D., Schapiro J.M., Richman D.D. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med. 2010, 18:156-163.
9. Maeda Y., Venzon D.J., Mitsuya H. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi- dideoxynucleoside resistance. J. Infect. Dis. 1998, 177:1207-1213.
10. Mao H., Thakur C.S., Chattopadhyay S., Silverman R.H., Gudkov A., Banerjee A.K. Inhibition of human parainfluenza virus type 3 infection by novel small molecules. Antiviral Res. 2008, 77:83-94.
11. Menendez-Arias L. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res. 2008, 134:124-146.
12. Micheva-Viteva S., Pacchia A.L., Ron Y., Peltz S.W., Dougherty J.P. Human immunodeficiency virus type 1 latency model for high-throughput screening. Antimicrob. Agents Chemother 2005, 49:5185-5188.
13. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263-267.
14. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyter J., De Clercq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 1988, 20:309-321.
15. Quinones-Mateu M.E., Arts E.J. HIV-1 fitness: implications for drug resistance, disease progression, and global epidemic evolution. HIV Sequence Compendium 2001 Theoretical Biology and Biophysics Group 2001, 134-170. Los Alamos National Laboratory, Los Alamos, NM. C. Kuiken, B. Foley, B. Hahn, P. Marx, F. McCutchan, J. Mellors, S. Wolinsky, B. Korber (Eds.).
16. Quinones-Mateu M.E., Arts E.J. Virus fitness: concept, quantification, and application to HIV population dynamics. Curr. Top. Microb. Immunol. 2006, 299:83-140.
17. Quinones-Mateu M.E., Soriano V., Domingo E., Menendez-Arias L. Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate. Virology 1997, 236:364-373.
18. Shirasaka T., Kavlick M.F., Ueno T., Gao W.Y., Kojima E., Alcaide M.L., Chokekijchai S., Roy B.M., Arnold E., Yarchoan R. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 1995, 92:2398-2402.
19. Thakur C.S., Jha B.K., Dong B., Das G.J., Silverman K.M., Mao H., Sawai H., Nakamura A.O., Banerjee A.K., Gudkov A., Silverman R.H. Small-molecule activators of RNase L with broad-spectrum antiviral activity. Proc. Natl. Acad. Sci. USA 2007, 104:9585-9590.
20. Westby M., Nakayama G.R., Butler S.L., Blair W.S. Cell-based and biochemical screening approaches for the discovery of novel HIV-1 inhibitors. Antiviral Res. 2005, 67:121-140.
21. Zhang Z., Walker M., Xu W., Shim J.H., Girardet J.L., Hamatake R.K., Hong Z. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother 2006, 50:2772-2781.